Breaking News, 7 December 2017: bluebird bio and TC BioPharm Announce Strategic Collaboration to Research and Develop Gamma Delta CAR T Cell Product Candidates for Cancer Immunotherapy

With a strong focus on allogeneic CAR-T therapies for treatment of cancer,      TC BioPharm’s mission is to develop and commercialise innovative cell-based products to target disease, improving patient health and Quality of Life.

TCB is currently developing next generation safe CAR-T products based on its patent protected, proprietary process using the clinically proven ImmuniCELL backbone.  We are a fully integrated bio-pharmaceutical company with GMP, regulatory, clinical and quality functions all in-house.

     We have a growing team based in our Glasgow and Edinburgh offices, alongside a wide range of scientific advisors              and partner organisations.